1 / 9

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. www.shift-study.com. Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

zinnia
Download Presentation

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systolic Heart failure treatment withthe Ifinhibitor ivabradine Trial Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  2. Outcomes in placebo patients grouped according to tertiles of systolic blood pressure and resting heart rate Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % Heart rate at baseline ≥81 bpm 74 to <81 bpm <74 bpm <115 mm Hg 115 to <130 mm Hg ≥130 mm Hg Systolic blood pressure at baseline P=0.0058 for difference between the groups www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  3. Outcomes in placebo patients according to tertiles of baseline systolic blood pressure Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % P=0.0003 for difference between the groups <115 mm Hg 115 to <130 mm Hg ≥130 mm Hg Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  4. Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure <115 mm Hg HR 0.84 (95% CI, 0.72 to 0.98), P=0.022 Placebo Incidence of primary end point (%) Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  5. Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure 115 to <130 mm Hg HR 0.86 (95% CI, 0.72 to 1.03), P=0.099 Incidence of primary end point (%) Placebo Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  6. Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Baseline systolic blood pressure ≥130 mm Hg HR 0.77 (95% CI, 0.66 to 0.92), P=0.003 Incidence of primary end point (%) Placebo Ivabradine Time (years) Numbers at risk www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  7. Effect of ivabradine on primary outcomes (CV death or HF hospitalization) according to systolic blood pressure level Rate of primary end point (cardiovascular mortality or hospitalization for worsening heart failure), % P for interaction =0.68 Baseline SBP <115 mm Hg Baseline SBP 115 to <130 mm Hg Baseline SBP≥130 mm Hg HR 0.84 (95% CI, 0.72 to 0.98), P=0.022 HR 0.86 (95% CI, 0.72 to 1.03), P=0.099 HR 0.77 (95% CI, 0.66 to 0.92), P=0.003 Placebo Placebo Placebo Ivabradine Ivabradine Ivabradine Time (years) Time (years) Time (years) www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  8. Effect of ivabradine on other outcomes according to baseline systolic blood pressure www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

  9. Adverse event leading to withdrawal according to systolic blood pressure level www.shift-study.com Komajda M et al. Eur J Heart Fail. 2014;16(7):810-816.

More Related